Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation

Published:2021-02-08 Issue:5 Volume:147 Page:1365-1378
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Keller Brian A.^ORCID,Laight Brian J.,Varette Oliver,Broom Aron,Wedge Marie-Ève,McSweeney Benjamin,Cemeus Catia,Petryk Julia,Lo Bryan,Burns Bruce,Nessim Carolyn,Ong Michael,Chica Roberto A.,Atkins Harold L.,Diallo Jean-Simon,Ilkow Carolina S.,Bell John C.

Funder

Terry Fox Research Institute

Institute of Cancer Research

Vanier Canada Graduate Scholarship

Canadian Graduate Scholarship - Master's

Natural Sciences and Engineering Research Council

Ontario Graduate Scholarship

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-021-03545-2.pdf

Reference53 articles.

1. Araujo RW, Paiva V, Gartner F, Amendoeira I, Oliveira JM, Schmitt FC (1999) Fine needle aspiration as a tool to establish primary human breast cancer cultures in vitro. Acta Cytol 43:985–990

2. Ascierto PA, McArthur GA, Dreno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandala M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, Larkin J (2016) Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17:1248–1260

3. Bowyer SE, Rao AD, Lyle M, Sandhu S, Long GV, McArthur GA, Raleigh JM, Hicks RJ, Millward M (2014) Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Res 24:504–508

4. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404

5. Coleman DT, Gray AL, Stephens CA, Scott ML, Cardelli JA (2016) Repurposed drug screen identifies cardiac glycosides as inhibitors of TGF-beta-induced cancer-associated fibroblast differentiation. Oncotarget 7:32200–32209

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High throughput screening identifies repurposable drugs for modulation of innate and acquired immune responses;Journal of Autoimmunity;2024-09

2. Pharmacogenetics in Oncology: A useful tool for individualizing drug therapy;British Journal of Clinical Pharmacology;2024-07-30

3. Unlocking the potential of dimethyl fumarate: enhancing oncolytic HSV-1 efficacy for wider cancer applications;Frontiers in Immunology;2023-12-19

4. Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen;Molecular Therapy;2022-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3